Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A phase II study from the North Central Cancer Treatment Group

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 29-34

  Jatoi, Aminah ^a   Murphy, B R ^b   Foster, N R ^a   Nikcevich, D A ^c   Alberts, S R ^a   Knost, J A ^d   Fitch, T R ^e   Rowland Jr , K M ^f  

^a MAYO CLINIC   (United States)

^b Toledo Community Hospital Oncology Program CCOP   (United States)

^c Duluth CCOP   (United States)

^d Illinois Oncol Res Assoc CCOP   (United States)

^e Scottsdale CCOP   (United States)

^f Carle Cancer Center CCOP   (United States)

Author keywords

Chemotherapy; Esophageal cancer; Metastatic; Oral therapy; Response rate

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACIDOSIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIA CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DYSPNEA; EMPYEMA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATEMESIS; HUMAN; HYPOKALEMIA; HYPOXIA; INFECTION; KIDNEY FAILURE; LOWER ESOPHAGUS SPHINCTER; LUNG DISEASE; MALE; MELENA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIA; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 29844455992     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj063     Document Type: Article

References (13)

1. Cassidy J, Tabernero J, Twleves C et al. XELOX: Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
2. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312.
3. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first-line and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-1766.
4. Makatsoris T, Kalofonos HP, Aravantinos G et al. A phase II study of capecitabine plus oxaliplatin: A new first-line option in metastatic colorectal cancer. Int J Gastrointestinal Cancer 2005; 35: 103-110.
5. Hong YS, Song SY, Lee SI et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15: 1344-1347.
6. Koizumi W, Saigenji K, Ujiie S et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64: 232-236.
7. Petrovic Z, Tarabar D, Doder R et al. Oxaliplatin and capecitabine as second line chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22: 299 (Abstr 1199).
8. De Vila F, Orditura M, Matano E et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649.
9. Diaz-Rubio E, Evans TR, Tabemero J et al. Capecitabine in combination with oxaliplatin: A phase I dose, escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13: 558-565.
10. Jatoi A, Foster N, Johnson P et al, Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer: A multi-institutional study from the North Central Cancer Treatment Group. Dis Esophagus 2004; 17: 292-296.
11. Blazeby JM, Kavadas V, Vickery CW et al. A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res 2005; 14: 387-393.
12. Duffy D, Santner T. Confidence intervals for a binomial parameter based on multi-stage tests. Biometrics 1987; 43: 81-93.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.